Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Brokerages
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating […]
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating […]
